Study of Acetazolamide Added to Standard Therapy for Treating Decompensated Chronic Heart Failure in Adults

What this Trial Is About

Researchers are evaluating the use of acetazolamide in patients with decompensated chronic heart failure CHF, a condition where the heart struggles with contraction and relaxation leading to symptoms like shortness of breath, swelling, and fatigue. CHF often results from high blood pressure or coronary artery disease, and about half of patients have a preserved left ventricular ejection fraction. This trial aims to study whether adding acetazolamide to standard diuretic therapy can reduce congestion and improve patient outcomes during acute heart failure worsening. Participants will be randomly assigned to either receive acetazolamide at a dose of 250 mg three times daily along with standard heart failure medications, or to receive standard therapy alone. The study focuses on the hospital stage of decompensation treatment, evaluating the effect of acetazolamide on reducing fluid retention and edema compared to usual care. Throughout the study, participants will be monitored for changes in decompensation over three days, urine output, weight loss, natriuresis, hospital and ICU stay duration, and survival up to 90 days. Clinical assessments will include symptom scoring and a 6-minute walk test. The trial includes follow-up assessments up to 90 days after treatment to evaluate longer-term outcomes and safety.

Acetazolamide Per os for Decompensation of Heart Failure